The incidence of cancer increases with age, from less than 25 cases per 100,000 people in age groups under age 20 to about 350 per 100,000 people among those aged 45–49, to more than 1,000 per 100,000 people in age groups 60 years and older.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-fluorspot-and-elispot-assay-market
Data Bridge Market Research analyses that the ELISpot and FluoroSpot assay market is expected to grow at a CAGR of 12.7% in the forecast period of 2021 to 2028 and is expected to reach USD 711.03 million by 2028. The increase in the incidence of chronic diseases is escalating the growth of ELISpot and FluoroSpot assay market.
Increase in the cases of Cancer drives the market further
The rising incidence of chronic disorders is due to lack of physical activities, rise in sedentary lifestyle, and the individual's genetic makeup. For instance, the prevalence in women is more due to biological factors and anatomy and smaller lungs in women than in men. Hence, the dust would quickly enter the lungs at a higher concentration, lack physical activities and changes in population demographics. As a result, there would be increased consciousness about the disease, treatment and preventive measures. It would lead to increased distribution of ELISpot and flurospot assays for timely diagnosis and an increase in research and development investments funds being granted by public-private organizations and government organizations.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2013 - 2018)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Assay Kits, Analysers, Supplementary Or Ancillary Products), By Source (Human, Mouse, Monkey And Others), Diseases (Infectious Diseases, Cancer, Autoimmune Diseases, Allergy And Others), Application (Diagnostic Applications, Research Applications,), End User (Hospitals & Clinical Laboratories, Research Institutes, Biopharmaceutical Companies And Others), Distribution (Direct Tender, Retail Sales)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Oxford Immunotec USA, Inc. (US), BD (US), R&D Systems, Inc. (US), Mabtech (Sweden), Thermo Fischer Scientific (US), Covalab, Inc. (France), CellCarta (Canada), Oxford BioSystems (UK), AUTOIMMUN DIAGNOSTIKA GMBH (Germany), DIACLONE SAS (France), Abcam plc (UK), Covance Inc. (US), Cellular Technology Ltd (US), U-CyTech (Netherlands), Bio-Techne (US), and MIKROGEN GmbH (Germany), among others
|
|
Data Points Covered in Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global ELISpot and FluoroSpot assay market is segmented on the basis of product type, source, diseases, applications, end user and distribution.
- On the basis of product type, the global ELISpot and FluoroSpot assay market is segmented into Assay Kits, Analysers, Supplementary Or Ancillary Products. In 2021, the assay kits segment is expected to dominate the ELISpot and FluoroSpot assay market with 79.78% market share because of the growing preference for cell-based assays in drug discovery and use of T-cell assays in cancer research.
- On the basis of source, the global ELISpot and FluoroSpot assay market is segmented into human, mouse, monkey and others. In 2021, human segment is expected to dominate the ELISpot and FluoroSpot assay market with 46.45% market share owing to the ease of detection of the cytokines in blood samples for detection of chronic diseases.
- On the basis of diseases, the global ELISpot and FluoroSpot assay market is segmented into infectious diseases, cancer, autoimmune diseases, allergy and others. In 2021, the infectious diseases segment is expected to dominate the ELISpot and FluoroSpot assay market with 40.43% market share because of escalating number of chronic infectious diseases and increased productivity towards the use of ELISpot and FluoroSpot assays.
- On the basis of application, the global ELISpot and FluoroSpot assay market is segmented into diagnostic and research applications. In 2021, the diagnostic application segment is expected to dominate the ELISpot and FluoroSpot assay market with 63.60% market share because of escalating number of chronic infectious diseases and use of point of care diagnostics during the pandemic.
- On the basis of end user, the global ELISpot and FluoroSpot assay market is segmented into hospitals and clinics, research institutes, biopharmaceutical companies and others. In 2021, hospitals and clinics segment is expected to dominate the ELISpot and FluoroSpot assay market with a 43.46% market share due to enhanced diagnostic infrastructure and healthcare insurance policies.
- On the basis of distribution, the global ELISpot and FluoroSpot assay market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the ELISpot and FluoroSpot assay market with 85.73% market share due to the availability of more number of contacts, enhanced cost savings and ensuring compliant engagements.
Major Players
Data Bridge Market Research recognizes the following companies as the major ELISpot and FluoroSpot assay market players Oxford Immunotec USA, Inc. (US), BD (US), R&D Systems, Inc. (US), Mabtech (Sweden), Thermo Fischer Scientific (US), Covalab, Inc. (France), CellCarta (Canada), Oxford BioSystems (UK), AUTOIMMUN DIAGNOSTIKA GMBH (Germany), DIACLONE SAS (France), Abcam plc (UK), Covance Inc. (US), Cellular Technology Ltd (US), U-CyTech (Netherlands), Bio-Techne (US), and MIKROGEN GmbH (Germany), among others.
Market Developments
- In May 2021, CellCarta announced in their press releases that the company had acquired Reveal Biosciences, a company that provides immunohistochemistry services to biopharma industries. This acquisition helped the company enhance their production management and thereby anticipated improving overall revenue.
- In April 2021, BD announced that the company will be presenting in virtual investor healthcare conferences "The Bank of America Securities 2021 Virtual Healthcare Conference" and "The UBS Global Healthcare Virtual Conference". This helped company in gaining more customers globally and improved revenue for future market.
- In April 2021, Mabtech announced in their website that the company launched their new products IFN-α (mAbs, ELISABASIC, and ELISpotBASIC) using mouse strain. They demonstrated that these kits are much better in detection than the available competitive kits of company, thereby improving their product portfolio.
- In February 2021, Thermo Fisher Scientific announced it had won six annual CMO Leadership Awards awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners evaluated by biopharma and biotech companies. It is estimated that this recognition is anticipated to strengthen the company's footprints in the global market and to lead to an upsurge in company's growth in the coming years.
- In January 2021, Mabtech announced their new Fluorspot kit launch on their website. This new Human IgG SARS-CoV-2 RBD FluorspotPLUS Kit is made specific to SARS-CoV-2 Receptor Binding Domain and other IgG producing cells in nature. Thereby, this further enhanced their focused category product portfolio.
Regional Analysis
Geographically, the countries covered in the ELISpot and FluoroSpot assay market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in ELISpot and FluoroSpot assay market during the forecast period
North America dominated the ELISpot and FluoroSpot assay market due to the presence of FDA approved ELISpot and FluoroSpot assays kits and health remuneration policies. North America will continue to dominate the ELISpot and FluoroSpot assay market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of rise in chronic infection and increase in elderly population within the region.
Asia-Pacific is estimated to be the fastest-growing region in ELISpot and FluoroSpot assay market
Asia-Pacific is expected to grow during the forecast period of 2021 to 2028 due to increased awareness regarding the treatment for wound care in the region. In addition to this, favourable reimbursement scenario is expected propel the market's growth rate in this region.
COVID-19 Impact Analysis
COVID-19 had a limited impact on the ELISpot and FluoroSpot assay market. Both public and government sectors suffered greatly due to the facing financial crises during the outbreak of COVID-19. Businesses were shut down in numerous countries because of the social distancing guidelines and the imposition of lockdown. The ELISpot and FluoroSpot assay market adversely affected by due to the low availability of raw materials. However, government bodies increased the support vaccine development due to the pandemic's economic and social burden. The initiatives taken by government led to an increase in the adoption of pyrogen testing products for COVID-19 research. The vaccine manufacturing increased owing to the outbreak of COVID-19. The bacterial endotoxin testing is considered as an important quality assurance measure for ensuring the safety of patients. . The ELISpot and FluoroSpot assay market is expected to witness healthy growth in post-pandemic as well owing to its application in combating various other epidemics in the future.
For more detailed information about the ELISpot and FluoroSpot assay market report, click here – https://www.databridgemarketresearch.com/reports/global-fluorspot-and-elispot-assay-market
